Canadian Journal of Gastroenterology and Hepatology / 2018 / Article / Tab 1

Research Article

Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals

Table 1

Baseline parameters of the study cohort by degrees of fibrosis.

F0-F2 (Metavir) 
N=118 
Absolute (relative) 
counts or mean ± SEM
F3 (Metavir) 
N=80 
Absolute (relative) 
counts or mean ± SEM
F4 (Metavir) 
N=170 
Absolute (relative) 
counts or mean ± SEM
P

Male sex58 (49.2)34 (42.5)75 (42.4)0.477

Age (years)53.64±1.33960.56±1.29761.08±0.743<0.0001

Duration of HCV infection (years)9.37±0.7210.82±0.7511.06±0.590.158

BMI26.17±0.5027.96±0.5126.94±0.350.037

genotype 1b93 (78.8)73 (91.3)149 (87.6)0.002
genotype 1a14 (11.9)5 (6.3)4 (2.4)
genotype 1 (unspecified)4 (3.4)2 (2.5)13 (7.6)
genotype 37 (5.9)04 (2.4)
genotype other000

Naïve53 (44.9)14 (17.5)43 (25.3)<0.0001
Experienced65 (55.1)66 (82.5)127 (74.7)

Relapse19 (32.2)35 (56.5)38 (30.9)0.009
Partial response9 (15.3)7 (11.3)14 (11.4)
Breakthrough5 (8.5)8 (12.9)14 (11.4)
Nonresponse26 (44.1)12 (19.4)57 (56.3)

HBsAg positive3 (2.5)01 (0.6)0.166

HIV positive000N/A

Treatment for hypertension33 (30.3)35 (46.7)72 (47.1)0.015

Treatment for dyslipidemia7 (6.4)11 (14.7)41 (26.8)<0.0001

Treatment for T2DM12 (10.2)12 (15.0)34 (20.0)0.078

 Diet only2 (20)5 (55.6)8 (30.8)0.024
 OAD only5 (50)4 (44.4)4 (15.4)
 Insulin3 (30)014 (53.8)

Extrahepatic manifestations23 (19.5)10 (12.5)15 (8.8)0.03

HCC1 (0.8)2 (2.5)5 (2.9)0.475

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.